Stem cell factor-induced leukotriene B4 production cooperates with eotaxin to mediate the recruitment of eosinophils during allergic pleurisy in mice

J Immunol. 2001 Jul 1;167(1):524-31. doi: 10.4049/jimmunol.167.1.524.

Abstract

The understanding of the mechanisms underlying eosinophil recruitment in vivo may aid in the development of novel strategies for the treatment of allergic disorders. In this study, we investigated the role of chemokines in the cascade of events leading to eosinophil recruitment in a stem cell factor (SCF)- and leukotriene B(4) (LTB(4))-dependent allergic pleurisy model in mice. The intrapleural administration of the eosinophil-active chemokines eotaxin, RANTES, and macrophage-inflammatory protein 1alpha (MIP-1alpha) induced a time- and dose-dependent eosinophil recruitment. Pretreatment with anti-eotaxin, but not anti-RANTES or anti-MIP-1alpha, blocked the recruitment of eosinophils following Ag challenge of sensitized animals, and significant eotaxin immunoreactivity was detected in the pleural cavity of these animals. Similarly, only the anti-eotaxin inhibited the eosinophil recruitment induced by injection of SCF in naive animals. However, blockade of SCF did not inhibit the release of eotaxin after Ag challenge of sensitized mice. Akin to its effects on SCF and in the allergic reaction, eotaxin-induced eosinophil recruitment was blocked by the LTB(4) receptor antagonist CP105696. Nevertheless, SCF, but not eotaxin, appeared to regulate the endogenous release of LTB(4) after Ag challenge. Finally, we show that low doses of eotaxin synergized with LTB(4) to induce eosinophil recruitment in the pleural cavity. Overall, the present results show that eotaxin and SCF-induced LTB(4) cooperate to induce eosinophil recruitment into sites of allergic inflammation. Cooperation between inflammatory mediators must be an important phenomenon in vivo, explaining both the ability of lower concentrations of mediators to induce a full-blown functional response and the effectiveness of different strategies at inhibiting these responses.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Cell Movement / immunology*
  • Chemokine CCL11
  • Chemokine CCL3
  • Chemokine CCL4
  • Chemokine CCL5 / administration & dosage
  • Chemokine CCL5 / analogs & derivatives
  • Chemokines, CC*
  • Cytokines / administration & dosage
  • Cytokines / physiology*
  • Injections, Intraperitoneal
  • Injections, Subcutaneous
  • Leukotriene B4 / biosynthesis*
  • Leukotriene B4 / physiology
  • Macrophage Inflammatory Proteins / administration & dosage
  • Male
  • Mice
  • Mice, Inbred BALB C
  • Ovalbumin / administration & dosage
  • Pleura / immunology
  • Pleura / pathology
  • Pleurisy / immunology*
  • Pleurisy / pathology
  • Receptors, Chemokine / antagonists & inhibitors
  • Respiratory Hypersensitivity / immunology*
  • Respiratory Hypersensitivity / pathology
  • Stem Cell Factor / administration & dosage*

Substances

  • Ccl11 protein, mouse
  • Chemokine CCL11
  • Chemokine CCL3
  • Chemokine CCL4
  • Chemokine CCL5
  • Chemokines, CC
  • Cytokines
  • Macrophage Inflammatory Proteins
  • RANTES, Met-
  • Receptors, Chemokine
  • Stem Cell Factor
  • Leukotriene B4
  • Ovalbumin